anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer. &lt;IMAGE&gt;
NEW MATERIAL:A 2-acylthiomethyl-4-phenoxybutyric acid derivative expressed by formula I (X is H, halogen, lower alkyl or lower alkoxy; R&lt;1&gt; is H or lower alkyl; R&lt;2&gt; is lower alkyl or phenyl). EXAMPLE:2-Acetylthiomethyl-4-phenoxybutyric acid. USE:A remedy for chronic rheumarthritis. PREPARATION:Formaldehyde in an amount of 1-2 molar equiv. is added to a compound expressed by formula II in the presence of 0.1-1.1 molar equiv. secondary amine (e.g., dimethylamine or piperidine) in pyridine at ambient temperature - 120 deg.C for 1-10hr to provide a compound expressed by formula III. A thiocarboxylic acid expressed by the formula R&lt;2&gt;COSH in an amount of 1-2 molar equiv. is added thereto in an organic solvent in the presence or absence of a basic catalyst at -20-100 deg.C for 0.5-24hr to afford the aimed compound expressed by formula I.
PROBLEM TO BE SOLVED: To obtain the subject promotive agent which has promotive effective for producing body heat and is useful for prevention or treatment for obesity or diabetic saccharide by formulating a compound which processes a specific partial structure and shows vitamin B1 effect. SOLUTION: The objective promotive agent is obtained by formulating a compound which has a partial structure of formula I (R&lt;1&gt; is an alkyl) and shows vitamin B1 effect, preferably a compound (salt) of formula II [R&lt;2&gt; is a (substituted) hydrocarbon group which may be linked through thio groups]. In the formula II, R&lt;1&gt; is preferably methyl group and R&lt;3&gt; is preferably a (phenyl) 1-7C alkyl or a (phenyl) 2-7C alkenyl. As the compound of formula II, e.g. N-(4- amino-2-methyl-5-pyrimidinyl) methyl-N-(2-allyldithio-4-hydroxy-1-methyl-1-butenyl) formamide is favorable. The compound of formula I is usually contained in the promotive agent in a proportion of 0.01-100 wt.%. The promotive agent is low in toxicity, high in safety and excellent in absorbency and stability and possesses catecholamine secretory effect.
The invention discloses a uveitis TCR marker and application thereof. The marker comprises at least one of amino acid/nucleic acid sequences shown as SEQ ID NO. 1-10 and 21-30. This marker sequence is referred to as the &#34;uveitis specific TCR sequence set&#34;. It was determined based on differential analysis of the epitope 3 (CDR 3) region of T Cell Receptor (TCR) markers in peripheral blood of a clinically significant number of patients diagnosed with uveitis versus healthy populations. The invention only needs RNA/DNA extracted from a very small amount of peripheral blood of a subject, and establishes a subject individuated T cell receptor sequence library based on a high-throughput sequencing method. The test results of the test sample of the subject are then aligned with the &#34;uveitis specific TCR sequence set&#34; to indicate the risk of developing a uveitis disease in the subject. The method has positive effects on the aspects of selecting a treatment scheme, judging prognosis and the like of clinical uveitis.
PROBLEM TO BE SOLVED: To obtain a remedy for rosacea, capable of improving failure in appearances caused by the rosacea, e.g. erythema, ruddy face, papula and pustule at a short time, and hardly causing side effects by including a microbial cell component of lactic acid bacteria as an active ingredient. SOLUTION: This remedy for rosacea contains a microbial cell component of lactic acid bacteria as an active ingredient. The lactic acid bacteria can be the bacteria belonging to one genus of Lactobacillus, Bifidobacterium, Enterococcus or the like. An extraction method of the microbial cell component is preferably the one of subjecting the microbial cells to lysing treatment by using a lytic enzyme, and further subjecting the treated microbial cells to heating treatment. An actinase a kitalase a lysozyme or the like can be used as the lytic enzyme. The heat-treating condition can be &gt;=100 deg.C, and is preferably the temperature capable of being treated by an autoclave (110-125 deg.C). The cell wall can be destroyed by using a physical method such as an ultrasonic treatment and a French press. The daily dose thereof for an adult is preferably 0.002-0.1 g/kg as an active ingredient.
A computer implemented comprehensive healthcare system (100) for providing healthcare services to public users and enterprise users includes an electronic communication device (102) capable of accessing a comprehensive healthcare services application running on a server (104) and a communication channel (106) for transferring &#39;information between the electronic communication device (102) and the server (104). The comprehensive healthcare services application includes a healthcare provider &#34;management module (108) for managing healthcare providers and healthcare practitioners, a healthcare products management module (110) for managing information about the healthcare products, a user management module (112) for managing the user information of the registered users, ratings and review module (114) for managing ratings and reviews from the users, a user appointment management module (116) for managing appointments of the users with the healthcare providers and healthcare practitioners, a healthcare associated services management module (118) for managing healthcare associated services providers, a loyalty reward point management module (120) for managing the loyalty reward points collected by the users for using the present comprehensive healthcare services application and crowd funding management module (124) for managing healthcare related crowd funding information. The user management module (112) of the comprehensive healthcare services application automatically identifies at least one relation between the users from online resources and automatically classifies the reviews and ratings from a number of users into general reviews and trusted reviews. The ratings and review module (114) prioritizes trusted reviews and ratings from the close friends and relatives of each user. The user appointment management module (116) allows the users to perform advanced and real-time appointment booking with healthcare providers and medical practitioners based on their operating schedule. The comprehensive healthcare services application running on the server (104) processes all the information and securely stores the information in a repository (122). The healthcare mobile and web application running on the electronic communication device (102) provides real-time information about healthcare providers and healthcare practitioners nearby the user.
The invention relates to the technical field of nano drug delivery systems, in particular to a CD47 signal-mediated targeting nanoparticle with photothermal and chemical kinetics treatment effects, and a preparation method and application thereof. The nanoparticle comprises a core formed by copper sulfide nanoparticle and a shell formed by cancer cell membrane integrated with CD47, sulfurBeta-lapachone is loaded in the mesoporous of the copper-melting nano-particle. The nanoparticles of the scheme mediate photo-thermal and chemical kinetics accurate treatment of breast cancer through a &#39; don&#39;t eat me &#39; signal. The nanoparticles generate photothermal treatment effect on tumor tissues under the irradiation of laser; lap production of H in breast cancer cells  2  O  2  And then converted to OH by catalysis of the CuS nanoparticles. By combining photo-thermal and chemical kinetics, the optimal breast cancer treatment effect is achieved. The technical scheme solves the technical problem that the nano-drug presentation system in the prior art is difficult to effectively avoid phagocytosis of macrophages, and has ideal application prospect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide complexes or fusions between two or more different cytokines.  &lt;P&gt;SOLUTION: There are provided protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety such as a region of an immunoglobulin. Methods of using the protein complexes and fusion proteins are also disclosed. The protein complexes and fusion proteins including at least two different cytokines molecules are provided, which are generally useful in a similar way to the targeting immunotherapy. These protein complexes and fusion proteins include other protein functional groups if necessary. Such protein complexes and fusion proteins provide the activity of the component of cytokines in a fixed ratio.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a histamine release inhibitor on the basis of knowledge that a substance derived from a mycelium of Phellinus linteus has inhibitory action on histamine release, and to provide a method for producing the same.  &lt;P&gt;SOLUTION: (1) The histamine release inhibitor comprises the substance derived from the mycelium of Phellinus linteus. (2) The histamine release inhibitor comprises an extract of Phellinus linteus with hot water. (3) The histamine release inhibitor comprises a methanol-soluble fraction in the extract of Phellinus linteus with hot water. (4) The histamine release inhibitor comprises a methanol-eluted fraction of the methanol-soluble fraction in the extract of Phellinus linteus with hot water adsorbed on an ion adsorbent. (5) The histamine release inhibitor comprises a component having 200-1,000 molecular weight in the methanol-eluted fraction. (6) The method for producing the histamine release inhibitor comprises making the histamine release inhibitor into dry powder and mixing the dry powder with another food powder.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
FIELD: medicine; medical technology.SUBSTANCE: inventions group relates to medicine and medical technology, namely to cardiovascular surgery. In case of hypothermia at 26°C and stopping the systemic IC, the damaged aortic arch is dissected. The mouth of the left subclavian artery is cut off and clamped. A distal anastomosis is formed with the descending part of the thoracic aorta by installing the distal part of the vascular prosthesis of the aortic arch inside the descending part of the thoracic aorta. After that, the &#34;skirt&#34; -cuff is sewn to the descending part of the thoracic aorta, then the systemic IR is restored through the additional branch of the aortic arch prosthesis. A clamp is applied to the proximal part of the arch prosthesis. An anastomosis is formed between the third branch of the trifurcation prosthesis and the left subclavian artery. An intervascular anastomosis is formed between the prostheses of the ascending part and the aortic arch. The main branch of the aortic arch prosthesis is clamped and, after the prevention of air embolism, cardiac activity is restored. On the beating heart, an end-to-end intervascular anastomosis is formed between the main jaws of the trifurcation prosthesis and the main jaws of the aortic arch prosthesis. After stabilization of hemodynamics, IC is completed. The specified method is implemented by means of a synthetic vascular prosthesis of the aortic arch, which includes a main branch, an additional perfusion branch and a &#34;skirt&#34; -cuff. The specified prosthesis is made by fixing a woven knitted cuff in the form of a flat ring to a linear vascular prosthesis of the aortic arch. Then an additional branch of the aortic arch prosthesis is formed by suturing a vascular synthetic prosthesis with a diameter of 8 mm to a linear vascular aortic arch prosthesis with a &#34;skirt&#34; -cuff. After that, the main branch of the aortic arch prosthesis is formed, for which the linear vascular prosthesis is sutured at an angle to the linear vascular aortic arch prosthesis with a &#34;skirt&#34; cuff and an additional branch. Then a multilayer coating is applied to the surface of the product, where the first layer is a layer of protein, the second is a layer of anticoagulant - heparin, the third is a layer of a biodegradable coating based on gelatin and drugs with antimicrobial and antiplatelet action, while glutaraldehyde is used as a crosslinking agent, and plasticizer - glycerin, then the resulting prosthesis is sterilized with ethylene oxide at 37°C.EFFECT: inventions group makes it possible to preserve cerebral, cardiac and visceral blood flow at the stage of end-to-end intervascular anastomosis between the main branch of the aortic arch prosthesis and trifurcation prosthesis on the beating heart in patients with dissection of the ascending part and the aortic arch.7 cl, 3 dwg, 1 ex
PURPOSE:To provide a dental material having improved hardness, tensile strength, flexural strength, etc., and extremely excellent processability and handleability, by compounding a small amount of silicon nitride whisker to a plastic dental material. CONSTITUTION:A resin for artificial tooth, denture base, artificial crown or restorative dental material, is compounded with &lt;= 20wt%, preferably 3-5wt% of silicon nitride whisker (preferably having a diameter of about 0.5mu and a length of about 100mu). For example, in the case of a resin for denture base (e.g. methacrylate polymer, polysulfone resin, etc.), the thickness can be decreased from the standard 1.3-1.4mm. to 0.7mm. without causing breakage and keeping high hardness and strength. The uncomfortable and disagreeable feeling to the palate can be decreased remarkably, and at the same time, a sufficiently high chewing capability can be attained.
PURPOSE:To produce a spherical-shaped clay mineral, which is a bulking agent giving a excellent moldability to rubber or plastics and a compounding agent giving an excellent touch for use to a cosmetics by spray-drying an aqueous solvent dispersion of a clay mineral having a water swelling property. CONSTITUTION:The clay mineral having a water swelling property (e.g., a silicate mineral belonging to a smectite group such as a natural or synthetic monmorillonite, a saponite and a hectrorite, etc., is dispersed into an aqueous solvent and is gelled. On this occasion the dispersion liq. is preferable to contain the &lt;=20wt% clay mineral having the water swelling property, more preferably 1-10wt%. Then the spherical shaped clay mineral is produced by spray-drying the dispersion liquid. Since the obtained clay mineral has a spherical shape, it is the excellent bulking agent giving a high moldability to plastics and rubber, etc., and the cosmetics having an excellent smoothy touch for use without variance is obtained by compounding it to the cosmetics as a dispersing and stabilizing agent.
According to various embodiments, an electronic device which predicts emotional conditions of a protected person, who uses an assistive walking device, based on a deep learning-based prediction model comprises a communication interface and a processor. The processor is set to acquire the protected person&#39;s lifelog data from the assistive walking device through the communication interface, analyze the lifelog data to determine whether there is any abnormal behavior in daily patterns of the protected person, and when there is an abnormal behavior in daily patterns, input specific lifelog data used for confirmation of the abnormal behavior into the deep learning-based prediction model to predict emotional conditions of the protected person, and perform specific actions corresponding to the predicted emotional conditions. The deep learning-based prediction model is trained based on the lifelog data of the protected person when there is an abnormal behavior in the daily patterns, response data regarding the emotional conditions of the protected person acquired from the protected person, and response data regarding the emotional conditions of the protected person acquired from a pre-registered protector of the person. The emotional conditions can be predicted as one of sadness, fear, loneliness, or anger. Other various embodiments are also possible. Therefore, the electronic device can analyze the lifelog data of the protected person to predict the emotional conditions of the person, and perform specific actions to improve the emotional conditions of the person.
A system and method are disclosed for determining eligibility of a card holder at a point of service by accessing personal identification information stored at a select application database. The system comprises a card holder identification card having a printed code identifying the card holder. A code server comprises a code database correlating card holder specific code record IDs and corresponding addresses associated with the select application database for providing personal identification information defining card holder eligibility. A processing device at the point of service is programmed to: read the card holder&#39;s printed code; convert the card holder&#39;s print code to a code record ID; and establish communication with the code server to transfer the card holder&#39;s code record ID to the code server. The code server is programmed to compare the received code record ID to the code database and return the address corresponding to the received code record ID to the processing device. The processing device is programmed to log onto the application database and use the returned address to download the personal identification information defining card holder eligibility for display on the processing device at the point of service.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new nuclear receptor termed the steroid and xenobiotic receptor (SXR), i.e. a new branch group of the nuclear receptor superfamily.  &lt;P&gt;SOLUTION: The SXR forms a heterodimer together with RXR(retinoid X receptor), reacts with hundreds of natural and synthetic substances having biological activity including therapeutic steroids as well as dietary steroids and lipids and induces transcription by binding with reaction elements present in steroid-inducible cytochrome P450 genes. The SXR receptor monitors aggregate levels of inducers for each one substance, instead of hundreds of receptors, to trigger production of metabolizing enzymes in a coordinated metabolic pathway. By administering agonists and antagonists of SXR to patients, a variety of therapeutic goals can be achieved through establishment of homeostasis depending on modulating metabolism of one or more endogeneous steroids or xenobiotics. An assay is provided for identifying steroid drugs likely causing drug interaction when administered to a patient in therapeutic amounts.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
This study aims to determine the effect of prehabilitation on patients\&#39; functional capacity and postoperative complications. It is a randomized trial including 112 patients undergoing colorectal surgery for cancer. Patients will be allocated to intervention group receiving 4 weeks trimodal prehabilitation (N=56) or control group receiving no prehabilitation (N=56). After surgery, both groups will follow 8 weeks rehabilitation based on Enhanced Recovery After Surgery (ERAS) guidelines. The primary endpoint is functional capacity, secondary outcomes include postoperative complications and a cost-effectiveness analysis. Multimodal prehabilitation is expected to increase functional capacity and lower postoperative complications.
A new plastic composition which is slow dissolving in aqueous media and can be used to slowly release medication or other additive ingredients in an aqueous environment, which plastic composition is prepared by cross-linking a hydrophilic colloid such as carboxymethyl cellulose gum or alginate gum with a crosslinking agent, usually a polyol such as propylene glycol, in a relatively nonreactive water soluble carrier such as glycerol. The total composition, including the carrier, sets up into a plastic gel, the consistency of which can be varied by varying proportions of ingredients. The reaction can be speeded or driven to a more completely cross-linked state by using a catalysts such as aluminum or calcium salts. Complexing agents can be included for complexing the catalysts and releasing it slowly throughout the reaction to slow the reaction down where desired. Generally, the reaction proceeds faster in a close to neutral or basic medium at pH&#39;&#39;s ranging up to 10 or 11 and slower in an acid medium at pH of 5 and below so the rate of reaction can be controlled by adjusting the pH. Usually the composition will contain medication or cosmetic additives or ingredients and it can be molded by extrusion or the like into any predetermined form, e.g., in the form of a ring. In a preferred form, the composition has excellent pressure sensitive adhesive properties and these properties are very pronounced where the hydrophilic colloid used is carboxymethyl cellulose.
1,235,409. Hydrazinoquinoline derivatives. SMITH KLINE &amp; FRENCH LABORATORIES. 25 Sept., 1969 [26 Oct., 1968], No. 47352/69. Heading C2C. Novel hydrazinoquinoline derivatives of the general formula wherein Het is a heterocyclic aryl group, R is a hydrogen atom or a C 1-4  alkyl group and R&lt;SP&gt;1&lt;/SP&gt; is a hydrogen or halogen atom or a C 1-4  alkyl, C 1-4  alkoxy or trifluoromethyl group, and pharmaceutically acceptable acid addition salts thereof are prepared by reaction of a hydrazinoquinoline of the general formula with a heterocyclic aldehyde of the general formula HetCHO, followed optionally by salification of the product. 2,6 - Dimethyl - 4 - hydrazinoquinoline is prepared by reaction of 4-chloro-2,6-dimethylquinoline with hydrazine hydrate. Pharmaceutical compositions having anticestode, antibacterial and antifungal activity comprise, as active ingredient, a hydrazinoquinoline derivative of the first general formula above or a pharmaceutically acceptable acid addition salt thereof, in association with a non- toxic diluent or excipient therefor, and may be administered orally.
PURPOSE:To obtain the titled cosmetic having extremely excellent stability, by preparing a W/O-type emulsion by adding water to an oily phase mixed with an oleophilic surfactant, and emulsifying the emulsion with water using a hydrophilic surfactant and an N-(long-chain acyl)amino acid soap. CONSTITUTION:An oleophilic surfactant having an HLB value of &lt;=9 (e.g. sorbitan fatty acid ester, sucrose fatty acid ester, etc.) is mixed in an oily phase such as vegetable oil, wax, etc. and then water is added to the mixture to obtain a W/O-type emulsion. The W/O-type emulsion is emulsified with water using a hydrophilic surfactant having an HLB value of &gt;=10 (e.g. polyglycerol monofatty acid ester, polyoxyethylene alkyl ether, etc.) in combination with an N-(long- chain acyl)amino acid soap to obtain a weakly acidic W/O/W-type emulsion cosmetic. When a water-soluble polymer is added to the outer aqueous phase of said emulsion, it acts as a protective colloid of the emulsion and the stability is further improved.